Allergan acquires Serica Technologies Morningside Technology Ventures.

Altman, Ph.D., CEO and Founder of Serica.D., General Partner at Prism. Many large medical device companies have weathered the storm and have shifted focus to future growth now. Serica provided a unique opportunity to utilize huge new marketplaces with a revolutionary technology also to acquire a little, highly productive R&D team with unique skill units around that technology. It was a difficult decision to market Serica, but the Allergan transaction provided the shareholders with an excellent come back while maintaining the capability to hold onto several high value indications within the Alacer spin-off.The medical response at two years was assessed according to the size of the lesion at research entry. Because of this analysis, the patients were split into two groups , and the between-group difference in the common lesion size at baseline was calculated with the use of Welch’s corrected unpaired t-test.00. For each kind of immune assay, the effectiveness of the immune response for no scientific response, partial clinical response, or complete medical response was operationally thought as a combination of the magnitude and breadth , and one patient got vaginal intraepithelial neoplasia. Both patients who received three vaccinations declined to receive the last vaccination due to inconvenience.